GlobeNewswire by notified

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Share

Company Announcement

COPENHAGEN, Denmark; November 15, 2022Genmab A/S (Nasdaq:GMAB) will increase its share capital by 57,442 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

997 shares at DKK 815.50,
3,175 shares at DKK 939.50,
1,219 shares at DKK 962.00,
9,005 shares at DKK 1,025.00,
3,390 shares at DKK 1,032.00,
197 shares at DKK 1,050.00,
6,282 shares at DKK 1,136.00,
9,200 shares at DKK 1,145.00,
200 shares at DKK 1,147.50,
204 shares at DKK 1,155.00,
1,682 shares at DKK 1,161.00,
2,404 shares at DKK 1,210.00,
2,378 shares at DKK 1,233.00,
16,953 shares at DKK 1,334.50, and
156 shares at DKK 1,408.00.

Proceeds to the company are approximately DKK 66.7 million. The increase corresponds to approximately 0.09% of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.

Pursuant to section 32 of the Danish Capital Markets Act No. 2014 of November 1, 2021, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 65,886,724 which is made up of 65,886,724 shares of a nominal value of DKK 1 each, corresponding to 65,886,724 votes. 

About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab’s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people’s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.

Contact:
Marisol Peron, Senior Vice President, Communications and Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-Fand other filingswith the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®;HexaBody in combination withthe HexaBody logo®; DuoHexaBody® and HexElect®.


Company Announcement no. 57
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Sportradar and Oddin.gg Ink AV Betting Agreement to Elevate and Expand Esports Reach28.3.2024 09:00:00 CET | Press release

PRAGUE, Czech Republic and ST. GALLEN, Switzerland, March 28, 2024 (GLOBE NEWSWIRE) -- Sportradar (NASDAQ: SRAD) and Oddin.gg, an award-winning B2B betting-solutions provider for esports, today announced they have entered into a multi-year strategic partnership to offer audiovisual streaming of Oddin’s exclusive esports content to Sportradar’s betting operator clients around the world. The deal will support Oddin.gg’s growth ambitions in the expanding global esports market, whose betting turnover was estimated to be €83 billion in 2023. It will extend the reach of Oddin.gg’s official competition content by leveraging Sportradar’s market leading position as an AV betting provider. Sportradar’s global network of 900+ betting operator clients will benefit from the opportunity to offer greater volume and a wider variety of live streamed esports events to their customers, increasing opportunities for engagement with existing and new betting markets. The partnership also paves the way for fu

Municipality Finance issues a EUR 50 million tap under its MTN programme28.3.2024 09:00:00 CET | Press release

Municipality Finance Plc Stock exchange release 28 March 2024 at 10:00 am (EET) Municipality Finance issues a EUR 50 million tap under its MTN programme On 3 April 2024 Municipality Finance Plc issues a new tranche in an amount of EUR 50 million to an existing benchmark issued on 26 April 2023. With the new tranche, the aggregate nominal amount of the benchmark is EUR 1.30 billion. The maturity date of the benchmark is 29 July 2030. The benchmark bears interest at a fixed rate of 3.125 % per annum. The new tranche is issued under MuniFin’s EUR 45 billion programme for the issuance of debt instruments. The offering circular, the supplemental offering circular and final terms of the notes are available in English on the company's website at www.munifin.fi/investor-relations. MuniFin has applied for the new tranche to be admitted to trading on the Helsinki Stock Exchange maintained by Nasdaq Helsinki. The public trading is expected to commence on 3 April 2024. The existing notes in the se

PunaMusta Media on toteuttanut medialiiketoiminnan kaupan Keskisuomalaiselle28.3.2024 09:00:00 CET | Press release

PUNAMUSTA MEDIA OYJ PÖRSSITIEDOTE 28.3.2024 KLO 10.00 PunaMusta Media Oyj on tänään 28.3.2024 toteuttanut tytäryhtiöidensä Sanomalehti Karjalainen Oy:n, Karelia Viestintä Oy:n ja PunaMusta Paikallismediat Oy:n koko osakekantojen myynnin Keskisuomalainen Oyj:lle. Medialiiketoiminta siirtyy Keskisuomalaisen omistukseen 1.4.2024. Samalla PunaMusta Media-konserni luopuu medialiiketoiminnastaan. PunaMusta Media Oyj tiedotti 31.1.2024 allekirjoittaneensa kauppakirjan medialiiketoiminnan myynnistä Keskisuomalainen Oyj:lle. Kaupan täytäntöönpano oli ehdollinen Kilpailu- ja kuluttajaviraston hyväksynnälle. Kilpailu- ja kuluttajavirasto ilmoitti hyväksyneensä kaupan 6.3.2024. Osakekauppojen velaton kauppahinta on 8,5 miljoonaa euroa, joka maksettiin kaupan toteuttamishetkellä. PunaMusta Media kirjaa konsernissa arvioidun myyntivoiton noin 10,2 miljoonaa euroa. Medialiiketoiminnan ulkoinen liikevaihto vuonna 2023 oli 17,6 miljoonaa euroa (19,0 miljoonaa euroa vuonna 2022), ja liiketulos oli 0,6 m

Invitation to Aspo's Capital Markets Day 202428.3.2024 09:00:00 CET | Press release

Aspo Plc Press Release March 28, 2024, at 10:00 Invitation to Aspo’s Capital Markets Day 2024 Aspo is pleased to invite investors, analysts and media representatives to Aspo's Capital Markets Day 2024. The event will be held in Helsinki and online. Date: Tuesday, May 14, 2024 Place: Allas Sea Pool Restaurant, Katajanokanlaituri 2A, Helsinki Time (EET): 9:15 Registrations 9:30 Presentations 12:00 Lunch from 12:30 Ship tours Aspo’s CEO Rolf Jansson together with members of the Group Executive Committee will host the event and provide current information on the company's business operations, strategy, and financial development. The presentations will be held in English. Each presentation will be followed by a Q&A session, where participants can post questions also through the webcast platform. Guests who are present at the event venue in Helsinki may also visit m/s Electramar, which is the first vessel of AtoB@C Shipping’s batch of 12 new electric hybrid vessels. The vessel will be moored

KH Group’s Annual Report 2023 published28.3.2024 08:45:00 CET | Press release

KH Group Plc Stock exchange release 28 March 2024 at 9:45 am EET KH Group’s Annual Report 2023 published KH Group has published its Annual Report for 2023 today. The Annual Report includes the Board of Directors’ Report, Financial Statements, Auditor’s Report as well as the Corporate Governance Statement and the Governing Bodies’ Remuneration Report. The Financial Statements are also published as an xHTML file in Finnish language in accordance with European Single Electronic Format (ESEF) reporting requirements. In line with the ESEF requirements, the Group’s primary statements and notes have been labelled with XBRL tags. The Annual Report, Corporate Governance Statement and the Governing Bodies’ Remuneration Report as well as the xHTML file are available on the Company’s website at www.khgroup.com and attached to this release. KH GROUP PLC FURTHER INFORMATION: CEO Lauri Veijalainen, tel. +358 46 876 1648 DISTRIBUTION: Nasdaq Helsinki Ltd Main media www.khgroup.com Sievi Capital is now

HiddenA line styled icon from Orion Icon Library.Eye